RT Journal Article
T1 Specific Cellular and Humoral Response after the Third Dose of Anti-SARS-CoV-2 RNA Vaccine in Patients with Immune-Mediated Rheumatic Diseases on Immunosuppressive Therapy
A1 Mohamed Mohamed, Kauzar
A1 Álvarez Hernández, María Paula
A1 Jiménez García, Carlos
A1 Guevara Hoyer, Kissy
A1 Freites, Dalifer
A1 Martínez Prada, Cristina
A1 Pérez Sancristóbal, Inés
A1 Fernández Gutiérrez, Benjamín
A1 Mato Chaín, Gloria
A1 Rodero, María
A1 Rodríguez de la Peña, Antonia
A1 Mulero, Teresa
A1 Bravo, Cecilia
A1 Toledano Martínez, María Esther
A1 Culebras López, Esther
A1 Mediero Valeros, Beatriz
A1 Pérez Segura, Pedro
A1 Sánchez Ramón, Silvia María
A1 Candelas Rodríguez, Gloria Del Mar
AB Objective: Data on cellular and humoral immunogenicity after the third dose of anti-SARS-CoV-2 vaccines in patients with immune-mediated rheumatic diseases (IMRDs) are scarce. Herein, we evaluated the adaptive immune response in IMRD patients treated with different immunosuppressive therapies (conventional synthetic disease-modifying antirheumatic drugs [csDMARDs], biological disease-modifying antirheumatic drugs [bDMARDs], and targeted synthetic disease-modifying antirheumatic drugs [tsDMARDs]) after the booster of the anti-SARS-CoV-2 vaccine to determine whether any drug reduced the vaccine’s response. Methods: A single-center prospective study was conducted, including patients presenting with IMRD and healthy controls (HC). Specific anti-SARS-CoV-2 interferon-gamma (IFN-γ) production was evaluated between 8–12 weeks after the third dose of the SARS-CoV-2 vaccine. In addition, anti-Spike IgG antibody titers were also measured. Results: Samples were obtained from 79 IMRD patients (51 women, 28 men; mean age 57 ± 11.3 years old): 43 rheumatoid arthritis, 10 psoriatic arthritis, 14 ankylosing spondylitis, 10 undifferentiated spondyloarthritis, and 2 inflammatory bowel disease-associated spondyloarthritis (IBD-SpA). In total, 31 HC (mean age 50.9 ± 13.1 years old, 67.7% women) were included in the study. Post-vaccine results displayed positive T-cell immune responses in 68 out of 79 (86.1%) IMRD patients (82.3% of those without prior COVID-19). All HC and IMRDs patients had an antibody response against the SARS-CoV-2 receptor-binding domain; however, the HC response was significantly higher (median of 18,048 AU/mL) than in IMRDs patients (median of 6590.3 AU/mL, p < 0.001). MTX and leflunomide were associated with lower titers of IgG and IFN-γ responses. Among bDMARDs, adalimumab, etanercept, and guselkumab are associated with reduced cellular responses. Conclusion: Our preliminary data show that the majority of our IMRD patients develop cellular and humoral responses after the SARS-CoV-2 booster vaccination, emphasizing the relevance of vaccination in this group. However, the magnitude of specific responses was dependent on the immunosuppressive therapy administered. Specific vaccination protocols and personalized decisions about boosters are essential for these patients.
PB MDPI
YR 2023
FD 2023-08-29
LK https://hdl.handle.net/20.500.14352/110636
UL https://hdl.handle.net/20.500.14352/110636
LA eng
NO Mohamed Mohamed, K.; Álvarez-Hernández, M.P.; Jiménez García, C.; Guevara-Hoyer, K.; Freites, D.; Martínez Prada, C.; Pérez-Sancristóbal, I.; Fernández Gutiérrez, B.; Mato Chaín, G.; Rodero, M.; et al. Specific Cellular and Humoral Response after the Third Dose of Anti-SARS-CoV-2 RNA Vaccine in Patients with Immune-Mediated Rheumatic Diseases on Immunosuppressive Therapy. Biomedicines 2023, 11, 2418. https://doi.org/10.3390/biomedicines11092418
NO 2023 Descuento MDPIRío Hortega (CM20/00098) y Juan Rodés (JR22/00018)
NO Instituto de Salud Carlos III
DS Docta Complutense
RD 3 abr 2025